Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) major shareholder Versant Venture Capital Vi, L. sold 89,990 shares of Monte Rosa Therapeutics stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $9.66, for a total value of $869,303.40. Following the completion of the transaction, the insider now directly owns 2,007,948 shares of the company's stock, valued at approximately $19,396,777.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Versant Venture Capital Vi, L. also recently made the following trade(s):
- On Friday, September 20th, Versant Venture Capital Vi, L. sold 1,132,566 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $6.53, for a total value of $7,395,655.98.
- On Friday, September 13th, Versant Venture Capital Vi, L. sold 9,269 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $6.16, for a total value of $57,097.04.
- On Wednesday, September 11th, Versant Venture Capital Vi, L. sold 541,897 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $6.00, for a total transaction of $3,251,382.00.
Monte Rosa Therapeutics Trading Down 1.6 %
Top "Sleeping Giant" Crypto In The Market Now
From Crypto 101 Media | Ad
Top "Sleeping Giant" Crypto In The Market Now
We're looking at potential returns that could rewrite your financial future.
Click here to discover our #1 crypto pick before it's too late
Shares of GLUE stock opened at $9.22 on Thursday. The firm has a fifty day simple moving average of $5.86 and a two-hundred day simple moving average of $5.00. Monte Rosa Therapeutics, Inc. has a 12 month low of $2.91 and a 12 month high of $12.40. The firm has a market capitalization of $565.86 million, a PE ratio of -4.12 and a beta of 1.43.
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.07. The business had revenue of $4.70 million for the quarter, compared to the consensus estimate of $3.20 million. On average, equities analysts predict that Monte Rosa Therapeutics, Inc. will post -1.89 earnings per share for the current fiscal year.
Institutional Trading of Monte Rosa Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of GLUE. Meeder Asset Management Inc. bought a new stake in Monte Rosa Therapeutics during the second quarter worth $38,000. SG Americas Securities LLC purchased a new position in Monte Rosa Therapeutics during the 3rd quarter worth $55,000. EntryPoint Capital LLC bought a new stake in shares of Monte Rosa Therapeutics in the 1st quarter worth $112,000. American Century Companies Inc. raised its holdings in shares of Monte Rosa Therapeutics by 46.0% in the second quarter. American Century Companies Inc. now owns 49,410 shares of the company's stock valued at $185,000 after purchasing an additional 15,562 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Monte Rosa Therapeutics by 92.5% during the first quarter. Acadian Asset Management LLC now owns 55,548 shares of the company's stock valued at $390,000 after purchasing an additional 26,687 shares in the last quarter. 79.96% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have commented on GLUE. Wedbush restated an "outperform" rating and issued a $11.00 price target on shares of Monte Rosa Therapeutics in a report on Thursday, September 12th. Wells Fargo & Company decreased their target price on Monte Rosa Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Monday, August 12th.
Read Our Latest Research Report on Monte Rosa Therapeutics
Monte Rosa Therapeutics Company Profile
(
Get Free Report)
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
